Searchable abstracts of presentations at key conferences in endocrinology

ea0032p232 | Clinical case reports – Pituitary/Adrenal | ECE2013

Bilateral third nerve palsy secondary to an apoplexy in a pituitary macroadenoma causing Cushing’s disease: a very rare complication of a rare entity

Juszczak Agata , Worth Claudia , Karavitaki Niki , Grossman Ashley B

Introduction: Bilateral 3rd nerve palsy is known in conditions such as diabetes mellitus, neurosarcoidosis, Guillain-Barre syndrome, multiple sclerosis, anterior or posterior communicating artery aneurysm or mesencephalic bleed/trauma. There are only single cases reported in association with pituitary adenoma or carcinoma, usually in the context of apoplexy. We describe a patient with Cushing’s disease and bilateral 3rd nerve palsy secondary to apoplexy in pituitary macro...

ea0028p43 | Clinical practice/governance and case reports | SFEBES2012

Disconnection hyperprolactinaemia in non-adenomatous sellar/parasellar lesions practically never exceeds 2000 mU/L

Korevaar Tim , Wass John , Grossman Ashley , Karavitaki Niki

Hyperprolactinaemia in association with a large sellar lesion could represent either tumoural secretion of prolactin (PRL) or stalk disruption by a non-prolactinoma: the differentiation has important therapeutic consequences. We have previously shown that based on currently used assays disconnection hyperprolactinaemia associated with non-functioning adenoma (NFA) practically never exceeds levels above 2000 mU/l. We aimed to verify our proposed disconnection hyperprolactinaemi...

ea0028p157 | Nursing practise | SFEBES2012

Outcome of patients with Graves’ disease after long-term follow-up: data from a Nurse-led Thyroid Clinic

Fazal-Sanderson Violet , Alberts Barbara , Grossman Ashley , Karavitaki Niki

A relapse rate of more than 50% is quoted for patients with Graves’ Disease (GD) treated with anti-thyroid drugs. Our aim was to audit the outcome/relapse rate and possible predictive factors in a series of patients managed in our Nurse-led Thyroid Clinic (NLTC). The notes of patients with newly-diagnosed GD seen in the NLTC between 2005–2011 who had completed 18 months of anti-thyroid drug were reviewed: 60 patients (48 females) were identified. After 18 months of t...

ea0025p164 | Diabetes, metabolism and cardiovascular | SFEBES2011

Chronic GH excess is associated with adenosine monophosphate-activated protein kinase (AMPK) threonine-172 phosphorylation changes that do not lead to changes in AMPK activity

Thomas Julia , List Edward , Kopchick John , Grossman Ashley , Korbonits Marta

GH influences multiple metabolic pathways. Excess GH (acromegaly) causes a distinct form of cardiomyopathy, which may progress to fulminant heart failure. AMPK is an energy conservation enzyme that modulates multiple areas of the cell stress response, inhibiting anabolism and promoting catabolism. AMPK is activated by phosphorylation at Thr172 and measurement of Thr172 phosphorylation is thought to correlate with enzyme activity. We investigated the influence of GH on cardiac ...

ea0021p303 | Pituitary | SFEBES2009

Oncogene-induced senescence occurs in human pituitary adenomas

Khan Munayem , Chahal Harvinder , Jordan Suzzane , Korbonits Marta , Grossman Ashley

Pituitary adenomas are benign tumours, which do not involve mutations in tumour suppressor genes or oncogenes. We have shown that the canonical Raf/MAPK and PI(3)K/Akt pathways are over-activated in these tumours, but their downstream effectors are modified to a much lesser extent. It is probable that the oncogenic mutations responsible for the initiation of these tumours therefore lies proximal to the convergence of these pathways, at or even upstream to the growth factor rec...

ea0077lb50 | Late Breaking | SFEBES2021

A plasma and serum 5-HIAA assay with comparable diagnostic performance in patients with neuroendocrine tumours

Ewang-Emukowhate Mfon , Subramaniam Krithika , Grossman Ashley , Lam Francis , Nair Devaki , Caplin Martyn

Introduction: Neuroendocrine tumours (NET) are a diverse group of neoplasms originating from cells within the diffuse endocrine system. Urine 5-HIAA is commonly used in the diagnosis and monitoring of patients with NET in particular small intestinal neuroendocrine tumour with carcinoid syndrome. Urine 5-HIAA collection over a 24 hour period and the potential exposure to acid preservative in the sample container, limit the use of urine 5-HIAA.Methods: Sam...

ea0050ep067 | Neuroendocrinology and Pituitary | SFEBES2017

A case of plurihormonal TSHoma presenting as meningitis

Khan Shoaib , Grossman Ashley , Cudlip Simon , Mohammadi Bahram Jaffar , Ansorge Olaf , Pal Aparna

This 22 year old lady presented with Haemophilus Influenza meningitis. Given an unusual organism, she had an MRI which revealed an incidental pituitary macroadenoma extending into the right cavernous sinus and breaching the anterioinferior wall of the pituitary fossa. Thyroid function showed raised T4 (24.7 pmol/L) and T3 (8.3 pmol/L) with unsuppressed TSH (1.75 munit/L). IGF-1 was also raised at 56.7 nmol/L (12–50.1 nmol/L).<p c...

ea0050ep067 | Neuroendocrinology and Pituitary | SFEBES2017

A case of plurihormonal TSHoma presenting as meningitis

Khan Shoaib , Grossman Ashley , Cudlip Simon , Mohammadi Bahram Jaffar , Ansorge Olaf , Pal Aparna

This 22 year old lady presented with Haemophilus Influenza meningitis. Given an unusual organism, she had an MRI which revealed an incidental pituitary macroadenoma extending into the right cavernous sinus and breaching the anterioinferior wall of the pituitary fossa. Thyroid function showed raised T4 (24.7 pmol/L) and T3 (8.3 pmol/L) with unsuppressed TSH (1.75 munit/L). IGF-1 was also raised at 56.7 nmol/L (12–50.1 nmol/L).<p c...

ea0087p14 | Poster Presentations | UKINETS2022

Somatostatin receptors in olfactory neuroblastoma: The rationale for peptide receptor radionuclide therapy

Porto Juliana , Hayes Aimee , Branton Alexander , Caplin Martyn , Alusi Martyn , Grossman Ashley

Olfactory neuroblastoma (ONB) is a rare neuroendocrine tumour with a slow onset of symptoms, and classically a propensity for recurrence and a poor prognosis. Due to its rarity, there is no agreed standard therapy, but treatment will usually include surgical resection, adjuvant radiotherapy and/or chemotherapy. However, such tumours very often show positive uptake on somatostatin receptor radionuclide scanning, and selective use of peptide receptor radionuclide therapy (PRRT) ...

ea0090ep721 | Pituitary and Neuroendocrinology | ECE2023

An international, simulated-use study assessing nurses’ preferences between two lanreotide syringes (Somatuline Autogel vs Pharmathen) for treatment of neuroendocrine tumours (NETs) and/or acromegaly: PRESTO 3

Ferone Diego , Martin Wendy , Williams Jessica , Houchard Aude , Pommie Christelle , Ribeiro-Oliveira Antonio , Grossman Ashley B

Introduction/Background: Patients with NETs and acromegaly are commonly treated with somatostatin analogues (SSAs), such as octreotide and lanreotide depot formulations. The Pharmathen syringe is now available in several European countries and the USA for lanreotide depot injection. When using SSAs, confidence in and ease of use with syringes is important for decision-making in long-term therapy.Aims: PRESTO 3 compared nurses’ preference for the Som...